Clinical Scorecard: Clinical and Safety Outcomes of Fecal Microbiota Transplantation for Clostridioides difficile Infection in South Australia
At a Glance
Category
Detail
Condition
Recurrent, refractory, severe, and fulminant Clostridioides difficile infection (CDI)
Key Mechanisms
Restoration of gut microbiota via fecal microbiota transplantation (FMT) using prescreened anaerobically processed frozen donor stool
Target Population
Patients with recurrent, refractory, severe, or fulminant CDI in South Australia
Care Setting
Hospital and clinical settings utilizing centralized FMT facilities
Key Highlights
Primary cure rate of FMT was 84% overall, with 88% for recurrent CDI and 76% for refractory CDI.
Repeat FMT achieved secondary cure in 74% of cases where initial treatment failed.
Serious adverse events occurred in 3% of patients; no deaths were directly attributable to FMT.
Guideline-Based Recommendations
Diagnosis
Diagnosis of CDI should consider severity ranging from mild to fulminant colitis.
Recurrent CDI is defined by multiple episodes following initial therapy.
Management
FMT is recommended for recurrent CDI and as a treatment option for severe and fulminant CDI refractory to antibiotics.
FMT product should be manufactured from prescreened donors under regulated conditions meeting good manufacturing practice standards.
Monitoring & Follow-up
Prospective recording of clinical outcomes and adverse events following FMT is essential.
Donor screening must be ongoing and include medical history and laboratory testing for infectious agents.
Risks
Extended-spectrum β-lactamase–producing organisms were a common reason for donor ineligibility.
Serious adverse events are rare but require monitoring; no direct FMT-related deaths reported.
Patient & Prescribing Data
220 patients with recurrent, refractory, severe, or fulminant CDI treated with FMT in South Australia from 2013 to 2023.
High efficacy observed with primary cure in 84% of cases; repeat FMT improves outcomes in initial failures; FMT is safe with low serious adverse event rates.
Clinical Best Practices
Use centralized facilities with strict donor prescreening and laboratory testing to ensure safety of FMT product.
Deliver FMT via colonoscopy, enema, or upper gastrointestinal routes based on patient condition and safety considerations.
Employ anaerobic processing and freezing of donor stool to maintain microbial viability.
Maintain prospective databases to monitor outcomes and adverse events for continuous quality improvement.
